Max Hallin

883 total citations · 1 hit paper
6 papers, 632 citations indexed

About

Max Hallin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Max Hallin has authored 6 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Max Hallin's work include Renal cell carcinoma treatment (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Max Hallin is often cited by papers focused on Renal cell carcinoma treatment (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Max Hallin collaborates with scholars based in United States. Max Hallin's co-authors include Dana D. Hu‐Lowe, Maren L. Grazzini, Michele McTigue, Brion W. Murray, Shinji Yamazaki, Karin Amundson, Grant Wickman, Robert S. Kania, Jeffrey H. Chen and David A. Rewolinski and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Max Hallin

6 papers receiving 620 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Max Hallin United States	6	362	276	260	142	61	6	632
Steve Bender United States	7	399 1.1×	259 0.9×	269 1.0×	148 1.0×	44 0.7×	9	650
K. T. Flaherty United States	15	461 1.3×	356 1.3×	256 1.0×	140 1.0×	53 0.9×	32	644
Alessandra Bulotta Italy	14	264 0.7×	406 1.5×	249 1.0×	124 0.9×	82 1.3×	47	695
Maren L. Grazzini United States	6	363 1.0×	249 0.9×	278 1.1×	156 1.1×	35 0.6×	8	629
Emmy D.G. Fleuren Netherlands	17	497 1.4×	368 1.3×	307 1.2×	108 0.8×	76 1.2×	25	871
Haby Henary United States	14	376 1.0×	378 1.4×	199 0.8×	117 0.8×	57 0.9×	32	702
Cuiju Tang China	14	382 1.1×	340 1.2×	240 0.9×	178 1.3×	96 1.6×	47	853
Loredana Militello Italy	9	355 1.0×	319 1.2×	197 0.8×	205 1.4×	106 1.7×	19	746
Raul Ayala United States	9	483 1.3×	356 1.3×	253 1.0×	124 0.9×	55 0.9×	18	830
Hideki Terai Japan	15	480 1.3×	297 1.1×	358 1.4×	199 1.4×	36 0.6×	41	778

Countries citing papers authored by Max Hallin

Since Specialization

Citations

This map shows the geographic impact of Max Hallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hallin more than expected).

Fields of papers citing papers by Max Hallin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Hallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hallin. The network helps show where Max Hallin may publish in the future.

Co-authorship network of co-authors of Max Hallin

This figure shows the co-authorship network connecting the top 25 collaborators of Max Hallin. A scholar is included among the top collaborators of Max Hallin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Hallin. Max Hallin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Karam, José A., Pavlos Msaouel, Surena F. Matin, et al.. (2021). A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC).. Journal of Clinical Oncology. 39(6_suppl). 312–312. 9 indexed citations

2.

Weber, Jeffrey S., Andressa S. Laino, Melinda Vassallo, et al.. (2020). Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10052–10052. 7 indexed citations

3.

Kashyap, Manoj Kumar, Deepak Kumar, Brett H. Simmons, et al.. (2017). Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 10(1). 112–112. 49 indexed citations

4.

Zhang, Cathy, Zhengming Yan, Cory L. Painter, et al.. (2009). PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts. Clinical Cancer Research. 15(14). 4630–4640. 45 indexed citations

5.

Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →

6.

Marrone, Tami, Dana D. Hu‐Lowe, Maren L. Grazzini, et al.. (2007). PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. Cancer Research. 67. 3992–3992. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact